Author Archives: admin


Human iPS Cell Characterization Kit Market to Garner Brimming Revenues with Comprehensive Analysis and Landscape Outlook to 2028- Merck KGaA, Takara…

The Human iPS Cell Characterization Kit (Induced pluripotent stem cell) contains a range of sensitive tools for the phenotypic assessment of the pluripotent status of human Embryonic stem & induced pluripotent Stem cells.

This report studies the Human iPS Cell Characterization Kit Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Human iPS Cell Characterization Kit Market analysis segmented by companies, region, type and applications in the report.

The report offers valuable insight into the Human iPS Cell Characterization Kit market progress and approaches related to the Human iPS Cell Characterization Kit market with an analysis of each region. The report goes on to talk about the dominant aspects of the market and examine each segment.

Key Players: Merck KGaA, Takara Bio, Thermo Fisher Scientific, BD Biosciences, Applied StemCell, Amsbio, Bio-Techne, ALSTEM, STEMCELL Technologies, System Biosciences, Applied Biological Materials, Creative Bioarray, Elixirgen Scientific, and Miltenyi Biotec

Get Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-human-ips-cell-characterization-kit-market-4457996?utm_source=dj&utm_medium=34

The global Human iPS Cell Characterization Kit market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Human iPS Cell Characterization Kit market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2022-2026.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Human iPS Cell Characterization Kit market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2027.

To understand the structure of Human iPS Cell Characterization Kit market by identifying its various sub segments.

Focuses on the key global Human iPS Cell Characterization Kit players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Human iPS Cell Characterization Kit with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Human iPS Cell Characterization Kit submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Key questions answered in this report

What will the market size be in 2027 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents: Human iPS Cell Characterization Kit Market

Chapter 1: Overview of Human iPS Cell Characterization Kit Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Make an enquiry before buying this report @ https://www.reportsandmarkets.com/sample-request/global-human-ips-cell-characterization-kit-market-4457996?utm_source=dj&utm_medium=34

About Us:

Our marketing research reports comprise of the best market analysis along with putting the right statistical and analytical information on the markets, applications, industry analysis, market shares, technology and technology shifts, important players, and the developments in the market. If you require any specific company, then our company reports collection has countless profiles of all the key industrial companies. All these reports comprise of vital information including the company overview, the company history, the business description, the key products & services, the SWOT analysis, the crucial facts, employee details, the locations and subsidiaries to name a few.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

The post Human iPS Cell Characterization Kit Market to Garner Brimming Revenues with Comprehensive Analysis and Landscape Outlook to 2028- Merck KGaA, Takara Bio, Thermo Fisher Scientific, BD Biosciences appeared first on Agency.

Read more here:
Human iPS Cell Characterization Kit Market to Garner Brimming Revenues with Comprehensive Analysis and Landscape Outlook to 2028- Merck KGaA, Takara...

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a…

LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(

The collaboration agreement is a transformative partnership that combines Sernovas Cell Pouch System technologies, which has demonstrated Phase 1/2 clinical proof-of-concept using human donor islets, with Evotecs iPSC-based beta cells. Incorporating Evotecs insulin-producing, ethically-derived beta cells within Sernovas Cell Pouch platform creates the potential to provide a functional cure for millions of people suffering from diabetes using a cGMP controlled and scalable off-the-shelf product.

With its long-standing beta cell development program, Evotec has demonstrated the ability to reliably produce an unlimited supply of high quality, stable, human iPSC-derived beta cells using its proprietary process for producing islet-like clusters in a quality-controlled scalable bioreactor process. These islet-like clusters have now been proven to be functionally equivalent to primary human islets in their ability to normalize blood glucose using in vivo models of type 1 diabetes (T1D).

The partnership provides Sernova a global exclusive option to license Evotecs iPSC-based beta cells for use in treating both type 1 and type 2 diabetes. In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of 15M and will make a further investment of 5M. Specifically, concurrently with the entering into the collaboration agreement, Evotec acquired a total of 12,944,904 common shares at a price of CAD $1.57 per share for gross proceeds to Sernova of $20,323,500. In addition, pursuant to an unconditional purchase warrant, Evotec will acquire, on or before August 31, 2022, a further 2,709,800 common shares at a price of CAD$2.50 per share for gross proceeds of $6,774,500. All of the securities issued to Evotec are subject to a four month hold period.

Further to the collaboration and Evotecs strategic equity investment, Dr. Cord Dohrmann, Chief Scientific Officer of Evotec will join Sernovas Board of Directors.

Dr. Philip Toleikis, President, and Chief Executive Officer of Sernova, commented, In tandem with our current clinical islet cell program, Sernova entered into multiple pharmaceutical research collaborations to identify the highest quality and most compatible iPSC cell technology, and validate the cells preclinically within our Cell Pouch System. Evotec is an iPSC powerhouse having dedicated many years and substantial resources to developing high quality and stable stem cell technologies for multiple therapeutic applications. In every sense, both as a global strategic partner and as an iPSC expert, Evotec has exceeded all our expectations and Dr. Dohrmanns appointment to Sernovas Board adds significant regenerative medicine depth and cell therapy expertise. Todays announcement of this joint iPSC beta-cell partnership completes the three pillars of our diabetes cell therapy platform. Alongside our clinically validated Cell Pouch System and recently acquired conformal coating immune protection technology, this now establishes a total regenerative medicine cell therapy solution for insulin-dependent diabetes.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented, We searched long and hard for the right partner. Sernova clearly ticks all boxes with their clinically validated Cell Pouch technology, which fits perfectly to Evotecs iPSC-based beta cells. Together we will progress a highly differentiated first-in-class beta cell therapy into clinical development with the common goal to bring a truly transformative therapy to insulin-dependent diabetic patients. The synergies of Evotecs and Sernovas technologies puts Sernova in position to become the worlds leader in beta cell replacement therapy. Our equity investment underlines our strategic interest in this collaboration with Sernova. I am very much looking forward to collaborating with Sernova on the project as well as contributing to their Board of Directors.

Sernova has acquired an option for an exclusive global license to Evotecs Induced Pluripotent Stem Cell (iPSC)-based Beta cells to treat patients with insulin-dependent diabetes. From an operational perspective, the preclinical development program(s) will be jointly funded by Sernova and Evotec until IND acceptance. Sernova has the right to exercise its option for an exclusive global license upon IND filing. Evotec will contribute its cell manufacturing capabilities through research, development and product commercialization and will decide in the future on the joint funding of clinical development. Upon commercialization, there will be a profit-sharing arrangement between the two companies, with the split being dependent on Evotecs participation in funding the clinical development program.

Joint Sernova / Evotec Conference Call and Webcast Details:

Date: Tuesday, May 17, 2022 Time: 8:30 am EDT US Toll Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID: 13730121 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1550130&tp_key=3de87cce1d

A simultaneous slide presentation will be available via the above webcast link.

ABOUT SERNOVA CORP AND THE CELL POUCH SYSTEM CELL THERAPY PLATFORM

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

The Cell Pouch, as part of the Cell Pouch System, is a proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. After implantation, the device incorporates with tissue, forming highly vascularized, native tissue chambers for the transplantation and function of therapeutic cells, that release proteins and hormones as required to treat disease.

The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase 1/2 clinical trial study at the University of Chicago. Encouraging interim results have been presented at several international scientific conferences.

For more information, please visit http://www.sernova.com

ABOUT EVOTEC AND iPSC

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanakas lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon for the discovery that mature cells can be reprogrammed to become pluripotent. Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotecs iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Companys proprietary EVOcells platform.

For further information contact:

Corporate and Investors: Sernova Corp Christopher Barnes Tel: (519) 858-5126 [emailprotected] http://www.sernova.com

Investors: Corey Davis, Ph.D. LifeSci Advisors, LLC [emailprotected] Tel: 212-915-2577

Media: Elizabeth Miller, MD LifeSci Communications [emailprotected]

FORWARD-LOOKING INFORMATION

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential and similar expressions, or that events or conditions will, would, may, could or should occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernovas management on the date such statements were made, which include our beliefs about the conduct and outcome of clinical trials, and the development of new technologies, cell therapy solutions and or products. The information disclosed represents results from one patient and may not be representative of all study patients or of the final study results. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Read the original:
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a...

Stem Cell Antibody Market Detailed Strategies, Competitive Landscaping and Developments for next 5 years Indian Defence News – Indian Defence News

Stem cell antibodies are the specialized cells which have the capacity to self-renew and differentiate to the specialized cell type such as neurons, liver and muscle cells. The Adult stem cells such as neural stem cells are multi potent. These have the ability to maintain and repair tissues where they are found. It has various applications such as developmental biology, disease modeling research, drug development screening and cell therapy studies. The methods of antibody detection such as immunocytochemistry and flow cytometry are most commonly used for stem cells and differentiated cell characterizations.

The latest study released on the Global Stem Cell Antibody Market by AMA Research evaluates market size, trend, and forecast to 2027. The Stem Cell Antibody market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.

Key Players in This Report Include:

Thermo Fisher Scientific, Inc. (United States), Merck Group (Germany), Abcam plc (United Kingdom), Becton, Dickinson and Company (United States), Bio-Rad Laboratories, Inc. (United States), Cell Signaling Technology, Inc. (United States), Agilent Technologies, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (United States), GenScript (United States),

Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.advancemarketanalytics.com/sample-report/48964-global-stem-cell-antibody-market

Market Drivers:

Market Opportunities:

Market Trend:

The Global Stem Cell Antibody Market segments and Market Data Break Down are illuminated below:

by Type (Primary Antibodies, Secondary Antibodies), Application (Developmental biology, Disease modeling research, Drug development screening, Cell therapy studies), Stem cell type (Adult stem cells, Embryonic (or pluripotent) stem cells, Induced pluripotent stem cells), Methods of detection (Immunocytochemistry, Flow cytometry)

Global Stem Cell Antibody market report highlights information regarding the current and future industry trends, growth patterns, as well as it offers business strategies to help the stakeholders in making sound decisions that may help to ensure the profit trajectory over the forecast years.

Have a query? Market an enquiry before purchase @ https://www.advancemarketanalytics.com/enquiry-before-buy/48964-global-stem-cell-antibody-market

Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:

Objectives of the Report

Buy Complete Assessment of Stem Cell Antibody market Now @ https://www.advancemarketanalytics.com/buy-now?format=1&report=48964

Major highlights from Table of Contents:

Stem Cell Antibody Market Study Coverage:

Browse Complete Summary and Table of Content @ https://www.advancemarketanalytics.com/reports/48964-global-stem-cell-antibody-market

Key questions answered

Contact US:

Craig Francis (PR & Marketing Manager)

AMA Research & Media LLP

Unit No. 429, Parsonage Road Edison, NJ

New Jersey USA 08837

Continued here:
Stem Cell Antibody Market Detailed Strategies, Competitive Landscaping and Developments for next 5 years Indian Defence News - Indian Defence News

Cell Expansion Market Analytical Overview, COVID-19 Impact Analysis, Growth Factors, Demand and Trends Forecast 2022 to 2030 Designer Women -…

Decision Foresight is working on new industry report named, Cell Expansion Market 2020-2030. According to the Decision Foresight, Cell Expansion Market held USD 16.68 Bn in 2021 and is to grow with a CAGR of 14.3% from 2022-2030.

The Decision Foresight is dedicated to provide you with an in-depth analysis of the various market based on its verticals, manufacturing process, products types, applications, end-users and regional analysis which further bifurcated into country level study. The study we provide covered the insightful data about all the channels related to your domain. In addition, the elaborated study of key market players involved in Cell Expansion Market gives predicted size of the market and opportunities in future.

Get sample of this report @ https://www.decisionforesight.com/request-sample/CUS020993

Market Segments:

The key segments covered in the report are:

Regional Analysis

Detailed regional and country-wise analysis, trend, forecasts has been covered in the report. The countries covered in the regional analysis of the report are (U.S., Canada, Mexico) in North America, (U.K., Germany, France, Italy, Spain, and Rest of Europe) in Europe, (China, India, Japan, Singapore, Malaysia, Australia, South Korea, Rest of Asia-Pacific (APAC)) in the Asia-Pacific (APAC), (Saudi Arabia, U.A.E, South Africa, Turkey, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and (Argentina, Brazil, and Rest of South America) as part of South America.

Market Report Scope

To Enquiry before Buy this Research Report or For Any Customization Ask:

@ https://www.decisionforesight.com/inquire/CUS020993

Key Players:

Global Cell Expansion Market report covers prominent players like thermo fisher scientific, inc. (us), danaher (us), becton, dickinson and company (us), lonza (switzerland), corning, inc. (us), merck kgaa (germany), sartorius stedim biotech (france), getinge ab (sweden) terumo corporation (japan), and miltenyi biotec (germany)

Key Points covered in the report:

Ask Industry Expert for Any Specific Query

@ https://www.decisionforesight.com/speak-analyst/CUS020993

Key questions answered in the report:

Purchase this Market Research Report Now @ https://www.decisionforesight.com/checkout/CUS020993

About US

Decision Foresight is a new-age market research company with a firm grip on the pulse of global markets. Decision Foresight Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

The collection of market intelligence reports is regularly updated to offer visitors ready access to the most recent market insights. We provide round-the-clock support to help you repurpose search parameters and thereby avail a complete range of reserved reports. After all, it is all about helping you reach an informed strategic decision about purchasing the right report that caters to all your market research demands.

Read More Reports:

Anaesthesia Face Masks Market:

https://www.decisionforesight.com/reports/anaesthesia-face-masks-market

Anaesthesia Monitoring Devices Market:

https://www.decisionforesight.com/reports/anaesthesia-monitoring-devices-market

Analgesics Market:

https://www.decisionforesight.com/reports/analgesics-market

Angiography Devices Market:

https://www.decisionforesight.com/reports/angiography-devices-market

Animal Health Market:

https://www.decisionforesight.com/reports/animal-health-market

Contact Us

Aloke Kumar,

Global Business Development Manager,

Decision Foresight

http://www.decisionforesight.com

Phone: +919875577842

Email: sales@decisionforesight.com;

aloke@decisionforesight.com

View original post here:
Cell Expansion Market Analytical Overview, COVID-19 Impact Analysis, Growth Factors, Demand and Trends Forecast 2022 to 2030 Designer Women -...

Technical Advancements & Innovative Products Likely to Expand Application of Surgical Meshes in Untapped Domains, States Fact.MR – BioSpace

Global Surgical Mesh Market Is Estimated To Be Valued At US$ 1.29 Bn In 2022, And Is Forecast To Surpass US$ 2.2 Bn Valuation By The End Of 2032

Sales of surgical meshes are expected to account for more than 21 Mn units by 2032-end, owing to their increasing application in untapped markets, says a Fact.MR analyst.

Fact.MR A Market Research and Competitive Intelligence Provider: The global surgical mesh market is estimated to exceed a valuation of US$ 1.29 Bn in 2022, and expand at a significant CAGR of 5.5% by value over the assessment period (2022-2032).

The availability of surgical meshes in absorbable and non-absorbable forms has expanded their application for temporary as well as permanent reinforcement. In recent years, demand for surgical meshes has escalated in aiding breast reconstruction as they reduce the exposure risk of the implant. Increasing health literacy in North America and Europe will create ample opportunities for surgical mesh manufacturers over the coming years.

Sedentary lifestyle and increasing obesity among the population have resulted in several chronic health issues. The consequent weakening of the muscles extends space for organ prolapse and hernia. Putting these organs back in place by stitching the muscles together can result in muscle tearing and the recurrence of prolapse. However, reinforcing the weakened muscles with the help of a surgical mesh has shown to decrease recurrence and increase the longevity of the repair.

For more insights into the Market, Get A Sample of this Report!

https://www.factmr.com/connectus/sample?flag=S&rep_id=6632

Key Takeaways from Market Study

Winning Strategy

To attract new customers, market players are focusing on portfolio enhancement. Robust investments in R&D are driving product innovation for key market players. Meshes inhibiting the growth of bacterial films and preventing tissue adhesions are luring new consumers. Collaboration of manufacturers with scientific personnel and operating surgeons have enabled bespoke designing of meshes to best fit patients needs.

Manufacturers are also aiming for portfolio expansion through acquisition and partnerships. Partnering with companies that offer a well-aligned portfolio has significantly increased consumer penetration for key manufacturers. However, augmenting relations with local players and operating surgeons will be a key determinant of the products commercial success.

For Comprehensive Insights Ask An Analyst Here

https://www.factmr.com/connectus/sample?flag=AE&rep_id=6632

Scientific collaborations and robust R&D investments have also guided product innovation and became a common strategic approach adopted by leading surgical mesh manufacturing companies to upscale their market presence.

For instance:

Surgical Mesh Industry Research by Category

Surgical Mesh Market by Product Type:

Surgical Mesh Market by Nature:

Surgical Mesh Market by Surgical Access:

Surgical Mesh Market by Use Case:

Surgical Mesh Market by Raw Material:

Surgical Mesh Market by Region:

Get Customization on this Report for Specific Research Solutions

https://www.factmr.com/connectus/sample?flag=RC&rep_id=6632

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global surgical mesh market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of product type (synthetic, biosynthetic, biologic, hybrid/composite), nature of mesh (absorbable, non-absorbable, partially absorbable), surgical access (open surgery, laparoscopic surgery), use case (hernia repair, pelvic floor disorder treatment, breast reconstruction, others), and raw material (polypropylene, polyethylene terephthalate, expanded polytetrafluoroethylene, polyglycolic acid, decellularized dermis/ECM, others), across seven major regions (North America, Latin America, Europe, East Asia, South Asia & ASEAN, Oceania, MEA).

Fact. MRs Domain Knowledge in Healthcare Division

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs

With a repertoire of over thousand reports and 1 million-plus data points, the team has analysed the healthcare domain across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services.

Check out more studies related to Healthcare Industry, conducted by Fact.MR:

Induced Pluripotent Stem Cell (iPSC) Market - Induced Pluripotent Stem Cell (iPSC) Market Analysis, By Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells), By Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering), By Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine) - Global Market Insights 2022 to 2026

Newborn Screening Market -Newborn Screening Market by Product (Newborn Screening Instruments, Consumables), by Test Type (Dry Blood Spot Tests, Hearing Tests, Critical Congenital Heart Disease (CCHD) Screening Tests), by Technology (Immunoassays & Enzymatic Screening Tests, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry, Others), by End User (Clinical Laboratories, Hospitals) and by Region- 2022 to 2032

Doxorubicin Market - Doxorubicin Market Analysis, By Formulation (Lyophilized Doxorubicin Powder, Doxorubicin Solution), By Cancer Type (Breast Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Stomach Cancer, Leukemia), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce) - Global Market Insights 2022 to 2026

Microplate Systems Market - Microplate Systems Market By Product (Readers, Pipetting Systems & Dispensers, Washers), By End User (Biotechnology & Pharmaceuticals, Hospitals & Diagnostic Laboratories, Research Institutes, Academic Institutes) & Region - Global Market Insights 2022 to 2026

Drug Discovery Services Market - Drug Discovery Services Market Analysis by Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization and Candidate Validation), by Type (Medicinal Chemistry, Biology Services, Drug Metabolism and Pharmacokinetics) Region Forecast- 2022-2032

Lab Automation Market - Lab Automation Market by Product (Equipment, Microplate Readers, Software & Informatics, Automated ELISA Systems, Automated Nucleic Acid Purification Systems), by Application (Drug Discovery, Clinical Diagnostics, Genomics Solutions, Proteomics Solutions), & Region - Forecast to 2021-2031

Animal Model Market - Animal Model Market Analysis by Species (Rats, Mice, Guinea Pig, Rabbits, Monkeys, Dogs, Pigs, Cats, and Other Species), by Application (Basic & Applied Research and Drug Discovery/Development) and Region Forecast- 2022-2032

Blood Flow Measurement Devices Market - Blood Flow Measurement Devices Market Analysis by Product (Ultrasound - Doppler Ultrasound, Transit time Flow Meters (TTFM), Laser Doppler), Application (Non-invasive - Cardiovascular Disease, Diabetes, Dermatology, Invasive - CABG, Microvascular Surgery), by Region - Global Forecast 2022-2032

Contrast Media Injectors Market - Contrast Media Injectors Market by Product (Consumables, Injector Systems, Accessories), Application (Radiology, Interventional Radiology, Interventional Cardiology), End-User (Hospitals, Diagnostic Imaging Centers), & Regional Analysis till 2032

Preclinical Imaging Market - Preclinical Imaging Market Analysis By Product (Modality, and Reagents), and Region Forecast- 2022-2032

About Us:

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and well be an able research partner.

Contact:

Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

Read the original post:
Technical Advancements & Innovative Products Likely to Expand Application of Surgical Meshes in Untapped Domains, States Fact.MR - BioSpace

Terumo Blood and Cell Technologies and GenCure collaborate to advance cell and gene therapy manufacturing solutions – Marketscreener.com

Lakewood, Colorado, US - Terumo Blood and Cell Technologies, a medical technology company specializing in a portfolio of products, software and services for blood component collection, therapeutic apheresis and cellular technologies, today announces it has signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions.

The latest agreement between Terumo Blood and Cell Technologies (Terumo) and BioBridge Global follows a series of long-running activities between the organizations for more than 20 years, including with a number of BioBridge Global's subsidiaries. It is anticipated that this latest agreement will extend into a broader collaboration with the full array of BioBridge Global's subsidiaries. Both parties have signed the new agreement to further combine technologies and expertise to cater to the demand across the cell and gene therapy (CGT) industry for smart systems that are automated and closed. These smart-systems allow for real-time response and refinement to the living therapies being produced inside the systems.

This collaboration will initially utilize expertise from Terumo and GenCure to establish a reference manufacturing center for BioBridge Global. This includes both organizations jointly developing core process and manufacturing operations. The reference site will enable GenCure to deliver a full solution for cell and gene therapy developers. It will be based at GenCure's process development and cGMP manufacturing facility at the VelocityTX campus in San Antonio, Texas, US.

Terumo will contribute a variety of products from its portfolio to allow in-plant optimization of processes and user feedback, along with investment in new products and process utilization. GenCure will leverage its highly developed expertise in Terumo Blood and Cell Technologies' cell collection, cell and gene therapy manufacturing and fill-finish equipment. This will significantly enhance its portfolio for developers requiring process optimization and manufacturing support.

The collaboration is scheduled to last three years and is in two phases. The first phase will enable Terumo to select from its portfolio of automated and closed-cell and gene therapy manufacturing devices and share the range of services offered at GenCure. This combination will help solve the critical industry gaps in manufacturing capacity and operational expertise. The second phase will allow GenCure and other BioBridge Global subsidiaries to use Terumo's data management solutions and value-added services to seamlessly transition between clinical and manufacturing sites by enabling chain-of-custody/identity and consistency of leukapheresis products.

Terumo selected GenCure as a key collaborator that has access under the BioBridge Global umbrella to all of the services needed for cell and gene therapy manufacturing that originates from blood products. These include donor recruitment, cell collections, cell selection and manufacturing facilities and biological testing services. The collaboration allows Terumo to link blood and cell collections with cell and gene therapy manufacturing. There is currently a critical lack of skills and knowledge bridging these areas.

"Despite the rapid evolution of the cell and gene therapy sector, critical challenges such as management between collection, manufacturing sites and logistics still remain unresolved. For over 20 years, Terumo has been working with BioBridge to provide safe, high-quality blood products," said Delara Motlagh, General Manager, Cell Therapy Technologies, Terumo Blood and Cell Technologies. "We are now combining our product portfolios, expertise and management to provide a vital link between cell collection sites and cell and gene therapy manufacturing sites, while addressing capacity and ensuring GMP production. This will provide a route to deliver cutting-edge cell and gene therapies through pursuing new standards of collection and manufacturing, including quality, consistency and demonstrated scalability."

Martin Landon, Chief Executive Officer of BioBridge Global said: "Across the cell and gene therapy sector, collaborations are now proving vital to the rapid development of solutions to a number of key challenges. Our donor-to-patient solutions, which include cell collection, manufacturing and testing, require the best technologies and expertise available in the market. Working with an innovator like Terumo Blood and Cell Technologies will allow us to provide a leading-edge end-to-end solution for cell and gene therapy manufacturing that will be vital to deliver advanced therapies to patients."

ENDS

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have more than 750 granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colo., US., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

About GenCure

GenCure, a subsidiary of San Antonio-based nonprofit BioBridge Global, provides process development and optimization expertise and cGMP manufacturing services for cell and cell-based advanced therapies companies as the anchor tenant for the VelocityTX landmark biotech innovation corridor complex. Working with its sister subsidiaries, GenCure understands and provides support for donor-to-patient services with a foundation in the critical elements related to clinical practice standards, access to source materials, testing services, research and development, and clinical research support. Learn more at GenCure.org.

About BioBridge Global

BioBridge Global (BBG) is a San Antonio, Texas-based 501(c)(3) nonprofit advanced therapies enterprise that offers diverse services through its subsidiaries - South Texas Blood & Tissue, QualTex Laboratories, GenCure and The Blood and Tissue Center Foundation. BBG provides products and services, donor recruitment and sample collection for a wide range of blood and tissue types, processing and manufacturing support, and testing of both donor and finished products for clients in the United States and worldwide. BBG is committed to saving and enhancing lives through the healing power of human cells and tissue. It enables advances in the field of regenerative medicine by providing access to human cells and tissue, testing services and biomanufacturing and clinical trials support. Learn more at BioBridgeGlobal.org.

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Visit link:
Terumo Blood and Cell Technologies and GenCure collaborate to advance cell and gene therapy manufacturing solutions - Marketscreener.com

Growing scope of Genetic Medicine and Stem Cell Research – The Hindu

Various career paths are available in the field of Genetic Medicine and Stem Cell Research Various career paths are available in the field of Genetic Medicine and Stem Cell Research

Among the various streams of science and medicine that have evolved with time, stem cell research and genetic medicine have risen as top contenders for various path-breaking discoveries. The treatment of more than 1,800 known monogenic hereditary disorders today, depends on the development of genetic medicines coupled with advanced stem cell research.

The field of genetic medicine comprises many areas, including the clinical practice of physicians, genetic counsellors and nutritionists, clinical diagnostic laboratory activities, and research into the causes and inheritance of genetic disorders. Simply put, it incorporates areas such as gene therapy, personalised medicine, and the rapidly emerging new medical speciality, including predictive medicine.

Stem cells are basically adaptable and versatile cells in ones body that are capable of complex actions, unlike conventional medication. These cells exist both in embryos and adult cells and can differentiate into any cell of an organism with the ability of self-renewal. Stem cell therapy uses these cells to treat or prevent a disease or condition. Also known as regenerative medicine, it promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

Amid a prevailing global healthcare crisis, stem cell research and genetic medicine have given us hope. The former was and continues to be an integral part of research conducted to treat COVID-19 symptoms, and genome sequencing has been extensively employed globally to analyse mutations and variations of the virus. In the coming years, the industry is only expected to grow.

Also, there is a general misconception that only people with medical education can take up jobs in these fields. This is not completely true because students who have studied Biology, B.Sc. graduates with at least one subject of the Biological Sciences, MBBS, B.Pharma, B.D.S., B.V.Sc. or B.E. Biotechnology students are eligible too.

Possible career options include Clinical geneticist, Genetic Counsellor, Clinical Researcher, Research Scientist, Biochemical Diagnostics Professional, Biomedical Research Assistant, Biomedical Technician, Cancer Research Scientist, Biomedical Engineer, Molecular Genetics Professional, Laboratory Technician, and Laboratory Director.

The writer is Senior Medical Director - LifeCell.

Excerpt from:
Growing scope of Genetic Medicine and Stem Cell Research - The Hindu

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types…

Sana Biotechnology, Inc

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune suppression

The islet autoimmune data suggest that cells with hypoimmune (HIP) edits evade allogeneic immune response and autoimmune response in a type 1 diabetes mouse model

Transplanting allogeneic cells into a non-human primate without immune suppression represents a key step toward development of engineered cells for the treatment of disease

SEATTLE, June 17, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, presented data showing survival of transplanted allogeneic, hypoimmune cells of several different types in a variety of locations in non-human primates (NHPs). The transplanted cells were induced pluripotent stem cell (iPSC)-derived cardiomyocytes, retinal pigment epithelium (RPE) cells, and islet cells, which were engineered to include Sanas hypoimmune gene modifications that enable immune evasion. Data were presented by Sonja Schrepfer, M.D., Ph.D., Head of Hypoimmune Platform at Sana, during sessions at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.

These data, demonstrating that three types of transplanted cells are able to survive and function in NHPs without immunosuppression, highlight the transformative potential of Sanas hypoimmune platform across a number of different cell types that can address a variety of diseases, said Steve Harr, Sanas President and Chief Executive Officer. As an example, the use of allogeneic islet transplant has had limited success in treating type 1 diabetes due to morbidities from the necessary immunosuppression. In contrast, our data indicate that we successfully engineered HIP human pancreatic islet cells to evade immune recognition, and these cells persisted and normalized glucose levels in in vivo models. We are applying the hypoimmune platform to a number of programs in our pipeline, including SC291, our CD19 targeted allogeneic CAR T therapy for blood cancers, with a goal of an IND this year, and SC451, our islet cell program with a goal of an IND for the treatment of type 1 diabetes in 2023.

Story continues

Transplanting cells or tissues from a donor to a different recipient currently requires intense immunosuppression to prevent rejection of the transplant. Sanas HIP platform goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition. The platform includes disruption of the major histocompatibility (MHC) class I and MHC class II expression to hide cells from the adaptive immune system, which includes antibody and T cell responses. These changes alone make cells susceptible to innate immune cell killing, in particular by natural killer (NK) cells. However, Sanas HIP platform additionally provides for evasion from innate cell killing, including via the overexpression of CD47, a molecule that protects HIP-modified cells from innate cell killing involving either NK cells or macrophages. HIP-modified pluripotent stem cells can serve as the starting material for the differentiation of specialized cell types to serve as cell-based therapeutics. Sanas goal is to use these HIP-modified cells to replace damaged or missing cells in the body in a number of different diseases, including, among others, cancer, type 1 diabetes, and cardiac disease.

Survival of HIP-modified islet cells for type 1 diabetes

Primary NHP pancreatic islet cells In this study, allogeneic primary pancreatic islet cells were HIP edited and transplanted intramuscularly into a healthy NHP without immunosuppression (n=1) as proof-of-concept. Islet cell survival was followed by in vivo bioluminescence imaging. The imaging showed that transplanted cells survived for the duration of the study (three months at data lock) with no evidence of a systemic immune response, including no T cell activation, antibody production, or NK cell activity as seen previously with other HIP edited cell types in NHPs (iPSC, cardiomyocytes, and RPE). Allogeneic unmodified primary pancreatic islet cells disappeared rapidly within 2 weeks.

Autoimmune mice Type 1 diabetes is a disease in which the patients immune system attacks and kills their pancreatic beta cells. Therefore, allogeneic transplanted cells in type 1 diabetes need to overcome both allogeneic and autoimmune rejection. Autoimmune diabetes arises spontaneously in non-obese diabetic (NOD) mice, and the pathophysiology of this disease shares many similarities with human type 1 diabetes. Since its development in 1980, this model has represented the gold standard of spontaneous disease models, allowing for investigation of autoimmune diabetes disease progression and susceptibility traits, as well as to test a wide array of potential treatments and therapies.

In this study, syngeneic or allogeneic mouse islet cells were transplanted intramuscularly without immunosuppression into diabetic autoimmune mice (n=15), split into three cohorts. The first cohort received unmodified syngeneic islet cells, the second cohort received unmodified allogeneic islet cells, and the third cohort received allogeneic HIP islet cells. The unmodified cells disappeared rapidly in the allogeneic setting (within 10 days) as well as in the syngeneic setting (within two weeks) due to autoimmune recognition. Neither cohort had a decrease in glucose levels. The HIP islet cells survived in all five diabetic mice for the duration of the study (one month at data lock), and glucose levels dropped, demonstrating therapeutic function of the HIP islet cells.

Survival of HIP-modified cardiomyocytes (iPSC-derived) In this study, allogeneic iPSC-derived cardiomyocytes were transplanted without immunosuppression into the hearts of healthy NHPs split into two cohorts. The first cohort received unmodified allogeneic iPSC-derived cardiomyocytes (WT; n=2), while the second cohort received allogeneic HIP iPSC-derived cardiomyocytes (HIP; n=4). The unmodified cells were almost eliminated in all NHPs, with significant T cell activation in addition to antibody production and binding. The HIP cardiomyocytes survived in all four monkeys for the duration of the study (up to two months at data lock), and there was no evidence of a systemic immune response, including no T cell activation, antibody production, or NK cell activity. After two months, injection sites were recovered, and local immune cells were analyzed for their donor-specific cell recognition and killing. While local immune cells kill unmodified cardiomyocytes, HIP cardiomyocytes were not recognized by these immune cells.

Survival of HIP-modified retinal pigmental epithelial (RPE) cells (iPSC-derived) In this study, allogeneic iPSC-derived RPEs were transplanted into the eye of healthy NHPs without immunosuppression split into two cohorts. The first cohort received unmodified allogeneic iPSC-derived RPE (WT; n=3), while the second cohort received allogeneic HIP iPSC-derived RPE (HIP; n=3). The unmodified cells were almost completely eliminated in all NHPs within three weeks, with significant T cell activation, antibody production and local microglial activation, demonstrating in this context that the eye is not an immunoprivileged site.

The HIP RPE survived in all three monkeys for the duration of the study (three weeks at data lock), and there was no evidence of a systemic immune response, including no T cell activation, antibody production, microglial or NK cell activity. Two weeks after the initial dose, the NHPs were re-injected with the same cell type into the second eye, so that the NHPs received a total of two doses. Unmodified WT RPEs again evoked a rapid systemic immune response in all NHPs, with activation of T cells and antibody production, and cells almost completely eliminate within one week. HIP RPE cells continued to survive even after re-injection without stimulation of adaptive or innate immune responses. These data suggest the potential to re-administer HIP RPE cells.

Sana intends to submit the data behind its presentations for publication in a peer-reviewed journal.

About Hypoimmune Platform Sanas hypoimmune platform is designed to create cells ex vivo that can hide from the patients immune system to enable the transplant of allogeneic cells without the need for immunosuppression. We are applying the hypoimmune technology to both pluripotent stem cells, which can then be differentiated into multiple cell types, and to donor-derived allogeneic T cells, with the goal of making potent and persistent CAR T cells at scale. Preclinical data demonstrates across a variety of cell types that these transplanted allogeneic cells are able to evade both the innate and adaptive arms of the immune system while retaining their activity. Our most advanced programs utilizing this platform include an allogeneic CAR T program targeting CD19+ cancers and stem-cell derived beta islet cells for patients with type 1 diabetes.

About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the Company, we, us, or our) within the meaning of the federal securities laws, including those related to the companys vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; the potential ability to make allogeneic, hypoimmune cells, including iPSC-derived cardiomyocytes, RPE cells, and islet cells, that survive and evade the immune system without immunosuppression and the potential persistence and efficacy of such hypoimmune cells; and the Companys expectations with respect to the submission and publication of data. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Companys strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Companys current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk factors identified in the Companys SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 10, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media: Nicole Keith Investor.relations@sana.com media@sana.com

Link:
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types...

Cell Culture Market 2022 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2030 – Digital Journal

Cell Culture Market: Introduction

According to the report, the globalcell culture marketwas valued at US$10.5Bn in 2020 and is projected to expand at a CAGR of9%from 2021 to 2031. The global cell culture market is driven by development of new products, technological advancements, and increase in use of single-use bioprocessing systems during the forecast period. The cell culture market in Asia Pacific is anticipated to expand at the fastest CAGR during the forecast period due to high unmet clinical needs, improvements in the healthcare infrastructure, and increase in focus on research & development activities.

Rise in Demand and Approvals for Biosimilar Products & Other Biologic Therapeutics to Drive Market

Cell culture is one of the most important steps for the production of biosimilar antibodies, as cell culture helps increase efficiency & productivity and reduce the cost of manufacture. The increase in demand & approvals for biosimilars products and other biologic therapeutics for the treatment of chronic diseases in developed as well as developing countries has led to the demand for efficient and cost-effective products. This is expected to drive the global cell culture market during the forecast period.

Get a sample of the report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405

Moreover, rise in demand for cost-effective and highly efficient cell culture products such as bioreactors, media, reagents, and sera for the production of high-yield cell lines has led to a surge in the number of new product launches. This is likely to provide lucrative opportunities in the global cell culture market during the forecast period. Major manufactures strive to expand their product portfolio by launching new and advanced systems for large-scale production, which is cost-effective and has low risk of contamination.

For instance, in 2018, Merck launched capsule filters that are designed to decrease the risk of contamination in a bioreactor. These filters are used for the separation of mycoplasma and bacteria from cell culture media. However, ethical issues associated with the use of fetal bovine serum, stringent regulations, and high cost of infrastructure for cell culture are projected to hamper the growth of global cell culture market during the forecast period.

Technological Advancements in Cell Culture Production Media & Instruments to Drive Demand for Protein-based Therapeutics

In terms of product, the global cell culture market has been classified into instruments, media, sera, and reagents. The instruments segment has been categorized into cell culture vessels (bioreactors), carbon dioxide incubators, biosafety cabinets, cryogenic tanks, and others. Technological advancements for improving the efficiency and reducing the risk of cross contamination are anticipated to propel the instruments segment during the forecast period.

The media segment has been split into chemically defined, classical media, protein free media, Lysogeny media, serum free media, and specialty media. The efficiency of different media used for cell culture production is expected to drive the media segment over the next few years.

The sera segment has been bifurcated into fetal bovine serum and others. Sera are used as cell culture supplements consisting of growth factors, nutrients, and other important trace elements. The reagents segment has been segregated into albumin, amino acid, attachment factors, growth factors & cytokines, protease inhibitor, thrombin, and others. Applications such as stem cell research have vast potential in future. Stem cell culture assists in standardization of drug production and enables production of a number of cell lines & related products.

Traditional pharmaceutical therapeutics help in treating only disease symptoms, whereas stem cell therapies assist in treating the cause of the disease. Hence, further research in the field of stem cell culture for development of drugs presents significant opportunities in the market in the near future.

Request for Analysis of COVID-19 Impact on Cell Culture Market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=405

Increase in Usage of Cell Culture Products in Drug Development & Manufacturing to Propel Pharmaceutical Companies Segment

Based on end-user, the global cell culture market has been divided into biotechnology companies, pharmaceutical companies, academic institutes, and research institutes. The pharmaceutical companies segment dominated the global market in 2020, and the trend is anticipated to continue during the forecast period due to increase in usage of cell culture products in drug development and manufacturing. The biotechnology companies segment is expected to account for a significant market share by 2031. The growth of the segment can be attributed to increase in the number of biotechnology companies and rise in strategic collaborations among market players to expand global presence.

Asia Pacific to Dominate Global Market

In terms of region, the global cell culture market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for a major share of the global market during the forecast period, owing to the presence of key players, increase in research & development activities, and new drug approvals.

Shift in trend toward continuous processing is expected to drive the cell culture market in North America. The cell culture market in Asia Pacific is at a pivotal point. Increase in focus of key players on expansion in the region, large untapped population, and rise in awareness about healthcare augment the cell culture market in Asia Pacific. For instance, Thermo Fisher expanded its Fisher BioServices and cryogenic service capabilities in Japan.

Thermo Fisher Scientific and Merck KGaA to Lead Global Market

Key players covered in this report are Sartorius AG, Thermo Fisher Scientific, Inc., Eppendorf AG, GE Healthcare, Corning Incorporated, Becton, Dickinson and Company, Merck KGaA, Lonza, VWR International, LLC, and PromoCell GmbH. Companies operating in the global cell culture market focus on strategic collaborations for developing new products in the emerging markets such as Asia Pacific and Latin America.

For instance, in May 2017, Merck announced the launch of EX-CELL Advanced HD perfusion medium, which helps increase the production yield and streamline the regulatory compliances.

Make an Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=405

Global Cell Culture Market: Segmentation

Cell Culture Market, by Product

Cell Culture Market, by End-user

More Related Reports by Transparency Market Research

perating Room Equipment Market: https://www.transparencymarketresearch.com/operating-room-equipment-market.html

Arterial Stents Market: https://www.transparencymarketresearch.com/arterial-stents-market.html

Personalized LASIK Surgery Market: https://www.transparencymarketresearch.com/personalized-lasik-surgery-market.html

Anastomosis Devices Market: https://www.transparencymarketresearch.com/anastomosis-devices-market.html

Electrosurgical Devices Market: https://www.transparencymarketresearch.com/electrosurgical-devices-market.html

Life Science Microscopy Devices Market: https://www.transparencymarketresearch.com/life-science-microscopy-devices.html

Ultrasonic Scalpels Market: https://www.transparencymarketresearch.com/ultrasonic-scalpels-market.html

PPE Kit Market: https://www.transparencymarketresearch.com/ppe-kit-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: [emailprotected]

Website: https://www.transparencymarketresearch.com/

See the rest here:
Cell Culture Market 2022 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2030 - Digital Journal

Stem Cell Cartilage Regeneration Market Strategic Insights of Developing Industry by Top Growing Prominent Players Profile: Anika Therapeutics, Zimmer…

Global Stem Cell Cartilage Regeneration MarketResearch Report provides key analysis on the market status of the Stem Cell Cartilage Regeneration with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe. The report also calculates the market size, Sales, Price, Revenue, Gross Margin, Market Share, cost structure, and growth rate. The report considers the revenue generated from the sales of This Report and technologies by various application segments and Browse Market data Tables.

The Stem Cell Cartilage Regeneration Market report covers the different market scenarios that have a direct impact on the growth of the market. The Stem Cell Cartilage Regeneration report study includes information on market factors such as the market dynamics, including drivers, restraints, challenges, threats, and potential growth opportunities, market trends, development patterns, financial information, latest technologies, innovations, leading competitors, and regional analysis of the market.

RequestMore Information on this Report (UseCorporate eMail ID to Get Higher Priority):https://www.worldwidemarketreports.com/sample/624293

The following Key Players are Mentioned in this Document:

Anika Therapeutics Zimmer Biomet BioTissue Technologies DePuy (Johnson & Johnson) Genzyme CellGenix EMD Serono Sanofi Aventis Smith & Nephew

Analysis ofStem Cell Cartilage RegenerationMarket by Type

Cell Based Approaches Non-cell Based Approaches

Analysis ofStem Cell Cartilage Regeneration Market by Application

Hyaline Cartilage Fibrocartilage Other

Get a Sample to Understand More Details on Stem Cell Cartilage Regeneration Market Segments:https://www.worldwidemarketreports.com/sample/624293

Regional Analysis for Stem Cell Cartilage Regeneration Market:

North America (U.S., Canada) Europe (U.K., Italy, Germany, France, Rest of EU) Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC) Latin America (Chile, Brazil, Argentina, Rest of Latin America) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

(*NOTE: To get customization to your liking you can ADD / REMOVE Key Players, Regions, and any other Segments as you need.)

How Covid 19 Affected the Stem Cell Cartilage Regeneration Market

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Impact Stem Cell Cartilage Regeneration market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations, travel bans, and quarantines, restaurants closed, all indoor/outdoor events restricted, over forty countries state of emergency declared, massive slowing of the supply chain, stock market volatility, falling business confidence, growing panic among the population, and uncertainty about future.

Get Specified Sample Containing COVID 19 Details:https://www.worldwidemarketreports.com/sample/624293

In this segment, we will give you the impact of COVID-19, how it affected the Stem Cell Cartilage Regeneration market, and how it will change the industrys future depending on the current government, private, and public situations. Our expert analysts keep an open eye on every situation that may change the flow of the industry which will help you make the best possible decision for your enterprise.

The objective of the study is to define the Stem Cell Cartilage Regeneration market sizes of different segments and countries in previous years and to forecast the values for the next five years. The report is designed to incorporate both qualified qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about crucial aspects such as drivers and restraining factors that will define the future growth of the Stem Cell Cartilage Regeneration market.

You can Buy This Report Here:https://www.worldwidemarketreports.com/buy/624293

Report Coverage

Why Choose Stem Cell Cartilage Regeneration Market Report?

Contact Us:

Worldwide Market Reports, Tel: U.S. +1-415-871-0703 U.K. +44-203-289-4040 Japan +81-50-5539-1737 Email: [emailprotected] Website: https://www.worldwidemarketreports.com/

Read the original here:
Stem Cell Cartilage Regeneration Market Strategic Insights of Developing Industry by Top Growing Prominent Players Profile: Anika Therapeutics, Zimmer...